Simendan
Simendan ((rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259) is a calcium-sensitizing positive inotropic vasodilator compound that enhances myocardial contractility through calcium-dependent binding to cardiac troponin C and selectively inhibits cardiac phosphodiesterase (Phosphodiesterase) III, while inducing coronary and peripheral vasodilation and anti-ischemic effects. Simendan can be used for research on congestive heart failure, acute heart failure, myocardial infarction, myocardial ischemia, and thrombotic diseases.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 131741-08-7
- Fòrmula: C14H12N6O
- Peso molecular:280.28
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
Simendan ((rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259) selectively inhibits cardiac phosphodiesterase III in purified enzyme preparations[1].
Simendan binds to cardiac troponin C in a calcium-dependent manner in paced papillary muscle preparations, combining positive inotropic effects with enhanced cardiac relaxation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (Male, 300-350 g, healed myocardial infarction via left anterior descending coronary artery ligation)[3]
-
Dosage:2.5 mg/kg
-
Administration:p.o.; ad libitum; 312 days
-
Result:Reduced mortality rate to 53% at day 312, representing a 28% risk reduction versus control.
Reduced 6-month mortality rate to 19%.
Achieved an infarct size of 43%.
Histological analysis showed an external normal boundary of 11.9 mm, internal normal boundary of 7.6 mm, external infarct boundary of 7.4 mm, internal infarct boundary of 6.2 mm, whole area of 60.7 mm2, normal area of 52.4 mm2, and infarct area of 8.2 mm2.
Chemical Information
-
No. CAS 131741-08-7
-
Peso molecular 280.28
-
Fòrmula C14H12N6O
-
SMILES
N#C/C(C#N)=N/NC1=CC=C(C2=NNC(CC2C)=O)C=C1
-
Synonyms
(rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Simendan Related Classifications
HY-W745845 Related Classifications
Powered by Bioz
Keywords
- Simendan
- 131741-08-7
- (rac)-Levosimendan
- (rac)-Simsndan
- (rac)-OR-1259
- Phosphodiesterase (PDE)
- myocardial infarction
- thrombotic diseases
- cardiac troponin C
- myocardial ischaemia
- cardiac phosphodiesterase III
- congestive heart failure
- ATP-sensitive potassium channels
- sarcoplasmic reticulum
- acute heart failure
- human platelet aggregation
- Inhibitor
- inhibitor
- inhibit